About
Technology
Issues
FAQ
Links
Official Page
IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.